Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have ...
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback